OncoSec Medical Inc.
200 South Virginia Street
390 articles with OncoSec Medical Inc.
OncoSec Medical Incorporated today announced that Interim CEO and Chief Operating Officer, Brian Leuthner , and Senior Vice President, Chief Clinical Development Officer, Sandra Aung , Ph.D., will participate in a fireside chat at the BTIG Virtual Biotechnology Conference
OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering
Mr. Silverman joins OncoSec with over two decades of electroporation device quality and manufacturing experience.
- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at the Raymond James Human Health Innovation Conference being held virtually Monday, June 21 st – Wednesday, June 23 rd , 2021.
Biotech industry veteran brings over 20 years of project and alliance management experience largely focused on oncology and clinical development
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device GenPulse™ for the Treatment of Solid Tumors
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced that it has received authorization to CE mark its proprietary next generation go-to-market gene delivery device, GenPulse™, a part of the OncoSec Medical System (OMS) electroporation device platform for use in solid tumors.
OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
Results From ILLUMINATE-301 To Be Discussed Webinar To Be Held on Wednesday, March 31, 2021 at 12:00 p.m. ET.
Biotech industry veteran brings more than 15 years of clinical development and leadership experience largely focused on Oncology, including the combination of cytokines and check-point inhibitors
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the addition of two new executives to the company's management team. Industry veteran Brian Leuthner has been appointed as OncoSec's Chief Operating Officer and Joe Smith has joined as Vice President of Business Development
OncoSec Medical Incorporated, a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.
-- Expanded access program enables patient with immune checkpoint inhibitor resistant metastatic melanoma to be treated with TAVOTM + pembrolizumab -- Patient with widely disseminated disease achieves responses in visceral tumors after extensive history of treatment failures
OncoSec Provides Highlights from Analyst & Investor Day and SITC 2020 and Announces KEYNOTE-695 Reaches Full Enrollment
-- Significance of 30% overall response rate (ORR), 6% complete responses (CR), durability and favorable safety data from KEYNOTE-695 Phase 2b trial discussed by Key Opinion Leaders (KOLs) specializing in melanoma treatment --
OncoSec Hosting an Investor and Analyst Day Webinar Showcasing Positive KEYNOTE-695 Data in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that it will host an Investor and Analyst webinar on Wednesday, November 11, 2020 from 8:30 am ET – 10:00 am ET showcasing interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial investigating TAV
OncoSec to Present Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020
-- KEYNOTE-695 abstract selected to be featured for discussion led by Dr. Adil Daud during Virtual Poster Walk -- -- Company Symposium featuring Dr. Paolo Ascierto's discussion of KEYNOTE-695 data to be held on November 12, 2020 at 7:30 a.m. ET -- -- Additional abstracts on CORVax12, OncoSec's COVID-19 vaccine candidate, and on TAVO in metastatic TNBC selected as poster presentations --
OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19
-- First next-generation DNA vaccine candidate to deliver spike (S) protein from SARS-CoV-2 plus immune-stimulating interleukin-12 (IL-12) to elicit T-cell activation and drive robust humoral immunity -- -- Providence St. Joseph Health, one of the national's leading non-profit health systems, and the Providence Cancer Institute to run Phase 1 clinical trial --
10/16/2020Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intra-tumoral cancer immunotherapies, today announced that Sandra Aung , Ph.D. joined the Company as Senior Vice President, Chief Clinical Development Officer. Dr. Aung will be responsible for overseeing K
OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO™ and Its Gene Delivery Platform
Patent Broadens Core Intellectual Property for the Intratumoral Delivery of Stimulatory Interleukins Using OncoSec's Proprietary Electroporation (EP) Technology Platform
OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the commencement of an investigator-initiated Phase 2 study led by Senior Member and Professor Ahmad A. Tarhini, M.D., Ph.D